Results 3,761-3,780 of 12,424 for speaker:Louise O'Reilly
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: It looked like a map of an underground from somewhere.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: It was very convoluted.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: Mr. Watt said he observed one of the PACE meetings in Scotland. Would it be fair to say be advocates were there on an equal footing and their contribution was-----
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: There is probably more said by what is left out than what is in the public domain.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: I thank the witnesses for being here. We respect and appreciate the job the witnesses do and we acknowledge that very often they are portrayed as the bad guys but sometimes they do not help their own cause. Patients come to us because they want to know the status of their approvals. They should not have to contact their local public representatives to get that information. It should be...
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: My question was about moving along through the process.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: The NCPE is not the only organisation involved.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: I acknowledge that but the witnesses are collectively representing the Department and the HSE. The progress is being tracked through all committees.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: In order to make a submission, patients submit an online form rather than participate in a one-to-one meeting.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: Do the witnesses accept that there is a problem with the current system? Do they accept that notwithstanding the work that has been done to bring families into the process to some degree, the families are still experiencing difficulty with the process and their level of involvement in it? I am not saying that the people in this room do not work hard; I fully appreciate that they do....
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: I asked the question of all the witnesses. I have not taken much time.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: With regard to the point------
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: I ask the Chair to allow me to finish as Mr. Flanagan's reply was not particularly fair.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: Mr. Flanagan stated that once people get the "Yes" answer, they go away. With respect, such people go back to looking after their loved ones who are struggling with an illness. It is not very fair to say they would not want to------
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: It might be more correct to state that the HSE does not follow up with such persons and ask what were their experiences of the system.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: That is fine. I thank Mr. Flanagan.
- Written Answers — Department of Finance: Insurance Industry (22 Nov 2018)
Louise O'Reilly: 20. To ask the Minister for Finance the steps he will take to ensure that residents affected by the liquidation of the structural warranty of an underwriter (details supplied) are not unfairly affected; and his plans to deal with this issue. [48604/18]
- Written Answers — Department of Health: Patient Safety (22 Nov 2018)
Louise O'Reilly: 150. To ask the Minister for Health if his attention has been drawn to the fact that a patient with tuberculosis was not isolated while at University Hospital Galway; and if disclosures of this incident have been made to him. [48774/18]
- Health (Regulation of Termination of Pregnancy) Bill 2018: Report Stage (27 Nov 2018)
Louise O'Reilly: 7 o’clock I have no intention of using seven minutes. This has been a long time coming and I do not want to intentionally make it any longer.` The vote in May was a vote to end the stigmatisation around access to abortion and, therefore, we should not be afraid to use words such as "abortion" or "access" - that is exactly what this is about. People did not vote for the...
- Health (Regulation of Termination of Pregnancy) Bill 2018: Report Stage (27 Nov 2018)
Louise O'Reilly: The members of the transgender community came to the fore and more than stepped up to the plate and played their part in the referendum campaign. The intention of the amendment is to make sure that nobody is left behind or excluded unintentionally because the intention is to make this legislation inclusive has been stated. We need to step that up. I am aware that the Minister met...